Literature DB >> 7733849

Neuropsychologic impairment in early HIV infection. A risk factor for work disability.

S M Albert1, K Marder, G Dooneief, K Bell, M Sano, G Todak, Y Stern.   

Abstract

OBJECTIVE: To explore the functional significance of incident neuropsychologic impairment among initially asymptomatic subjects infected with human immunodeficiency virus.
DESIGN: Prospective, observational cohort study of homosexual and bisexual men to examine the incidence of work disability related to the onset of neuropsychologic impairment.
SETTING: A university clinical and behavioral research site in New York City. PARTICIPANTS: Sample of 207 homosexual and bisexual men; 123 were seropositive and 84 were seronegative. PRINCIPAL OUTCOME MEASURES: Incident work disability in the course of 4.5 years of follow-up, with disability defined as a persistent (> or = 24 months) change in work hours (from 20 or more to less than 20 h/wk).
RESULTS: Compared with seronegative control subjects (n = 72), the relative risk of work disability among initially asymptomatic seropositive men (n = 44) was 2.76 (95% confidence interval, 1.2 to 6.5), nearly a threefold increase. Proportional hazards models show that this increased risk is attributable to the development of major neuropsychologic impairment in a subset (eight of 44) of the initially asymptomatic men, which is significantly associated with incident work disability (6/8 [75%]). Adjusting for symptom status and CD4+ cell count at the time of disability did not eliminate the increased risk associated with neuropsychologic impairment.
CONCLUSIONS: In this cohort, the increased risk of work disability among initially asymptomatic human immunodeficiency virus-positive men was related to incident neuropsychologic impairment; such impairment predicted work disability independently of symptom status and CD4+ cell count over the follow-up period. Neuropsychologic impairment in the course of human immunodeficiency virus infection may indicate increased risk for poor outcomes over and above that associated with systemic disease.

Entities:  

Mesh:

Year:  1995        PMID: 7733849     DOI: 10.1001/archneur.1995.00540290115027

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  38 in total

1.  The functional impact of HIV-associated neuropsychological impairment in Spanish-speaking adults: a pilot study.

Authors:  Monica Rivera Mindt; Mariana Cherner; Thomas D Marcotte; David J Moore; Heather Bentley; Maria M Esquivel; Yanira Lopez; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2003-02       Impact factor: 2.475

Review 2.  Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness.

Authors:  Thomas L Patterson; Brent T Mausbach
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

3.  Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

Authors:  Susanne May; Scott Letendre; Richard Haubrich; J Allen McCutchan; Robert Heaton; Edmund Capparelli; Ronald Ellis
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-10       Impact factor: 4.147

Review 4.  Neurocognitive impact of antiretroviral treatment: thinking long-term.

Authors:  Megan E McPhail; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

Review 5.  An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?

Authors:  Anantha Ram Nookala; Joy Mitra; Nitish S Chaudhari; Muralidhar L Hegde; Anil Kumar
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Feasibility and Acceptability of Ecological Momentary Assessment of Daily Functioning Among Older Adults with HIV.

Authors:  Raeanne C Moore; Christopher N Kaufmann; Alexandra S Rooney; David J Moore; Lisa T Eyler; Eric Granholm; Steven Paul Woods; Joel Swendsen; Robert K Heaton; J C Scott; Colin A Depp
Journal:  Am J Geriatr Psychiatry       Date:  2016-12-01       Impact factor: 4.105

Review 7.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

8.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

Review 9.  Protease resistant protein cellular isoform (PrP(c)) as a biomarker: clues into the pathogenesis of HAND.

Authors:  Bezawit Megra; Eliseo Eugenin; Toni Roberts; Susan Morgello; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-25       Impact factor: 4.147

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.